Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models
Fabian F. Pusch(Humboldt-Universität zu Berlin), Anton G. Henssen(Charité - Universitätsmedizin Berlin)
Cited by 3
Related Papers
ecDNA hubs drive cooperative intermolecular oncogene expression
|Nature|2021|334
Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma
|JCI Insight|2019|33
What Is Extrachromosomal Circular DNA and What Does It Do?
|Clinical Chemistry|2020|28
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
|Molecular Cancer Therapeutics|2023|17
Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer
|Cancer Discovery|2024|16